Authors

Panagiotis A. Konstantinopoulos, MD, PhD

Panagiotis A. Konstantinopoulos is the director of the Mellen and Eisenson Family Center for BRCA and Related Genes, director of Translational Research in the Division of Gynecologic Oncology, and the Velma Eisenson Endowed Chair for Clinical and Translational Research at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School.

Latest:

Optimized Immunotherapy Use and Novel Therapeutic Targets Move the Needle for Endometrial Cancer Management: With Ursula A. Matulonis, MD; and Panagiotis (Panos) A. Konstantinopoulos, MD, PhD

Drs Matulonis and Konstantinopoulos discuss the different subtypes of endometrial cancer and treatment developments for this disease.

Panayiotis S. Savvides, MD

Latest:

Dr. Savvides on the Risk of COVID-19 in Patients With Cancer

Panayiotis S. Savvides, MD, discusses COVID-19 precautions for patients with lung cancer.

Panelists Francis P. Arena, MD, NYU Langone

Panelists Ian Flinn, MD, Sarah Cannon Research Institute

Panelists Jacqueline Barrientos, MD, Zucker School of Medicine at Hofstra/Northwell

Panelists Johanna Bendell, MD, Sarah Cannon

Paolo A. Ascierto, MD

Paolo A. Ascierto, MD, is the director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, at the National Tumor Institute Fondazione G. Pascale.

Latest:

Dr Ascierto on First-Line Treatment Selection in Advanced BRAF+ Melanoma

Paolo A. Ascierto, MD, discusses findings from the SECOMBIT and DREAMseq trials and their implications for first-line treatment selection for patients with BRAF-mutant melanoma.

Paolo Ghia, MD

Paolo Ghia, MD, PhD is a Full Professor in Medical Oncology at the Università Vita-Salute San Raffaele and Head of the Laboratory of B-Cell Neoplasia at the affiliated IRCCS Ospedale San Raffaele. He is Director of the Strategic Research Program on CLL, a clinical Unit at the hospital, where he acts as National Coordinator or Principal Investigator in Phase 1-3 clinical trials in CLL.

Latest:

Dr Ghia on the Implications of Data From CAPTIVATE for Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL

Paolo Ghia, MD, provided insights into the significance of updated data from the final analysis of the phase 2 CAPTIVATE study in CLL/SLL.

Parameswaran Hari, MD, MRCP

Latest:

Examining the Importance of the Institutional Perspectives in Cancer Webinars

Jason Porter, MD, Subramanian Janakiraman, MD, Natalie S. Calendar, MD, Parameswaran Hari, MD, MRCP, and Kevin Kalinsky, MD, MS, discuss the importance of the Institutional Perspectives in Cancer webinars.

Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin

Latest:

Narsoplimab Trial Results

The panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.

Parminder Singh, MD

Latest:

Dr. Singh on Potential Implications of the IMvigor130 Trial in Bladder Cancer

Parminder Singh, MD, discusses potential implications of the phase III IMvigor130 trial in advanced bladder cancer.

Partow Kebriaei, MD

Latest:

Dr Kebriaei on the Potential Shift Away From Transplant in ALL

Partow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.

Pascale Guitera, MD

Latest:

Dr. Guitera on the RADICAL Trial for Melanoma

Pascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, the University of Sydney, discusses the RADICAL trial of patients with melanoma.

Pashtoon M. Kasi, MBBS, MD, MS

Latest:

Dr Kasi on the Rationale for Analyzing ctDNA to Inform Chemotherapy Decisions in CRC

Pashtoon Murtaza Kasi, MD, MS, discusses outcomes from an interim analysis of the BESPOKE CRC study and highlights the use of circulating tumor DNA for informing adjuvant chemotherapy treatment decisions for patients with stage II/III colorectal cancer.

Pashtoon M. Kasi, MD, MS

Latest:

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

Pashtoon M. Kasi, MD, MBBS, MS

Latest:

Audience Q&A: Best Practices in Managing HER2-Amplified CRC

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.

Pasi A. Jänne, MD, PhD

Pasi A. Jänne, MD, PhD, is senior vice president for Translational Medicine, director of the Belfer Center for Applied Cancer Science, director of the Chen-Huang Center for EGFR Mutant Lung Cancers, a senior physician, and the David M. Livingston, MD, Chair at Dana-Farber Cancer Institute; as well as a professor of medicine at Harvard Medical School

Latest:

Dr Jänne on Selecting a Combination Regimen in First-Line EGFR+ NSCLC

Pasi A. Jänne, MD, PhD, discusses considerations for selecting a frontline combination regimen in EGFR-mutated NSCLC.

Pasi A. Janne, MD, PhD, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Harvard University

Pat W. Whitworth, MD

Latest:

Dr. Whitworth on Treating Breast Cancer With Chemo

Dr. Pat Whitworth, from the Vanderbilt University Medical Center, Discusses Chemotherapy for Breast Cancer

Pat Whitworth, MD

Latest:

Dr. Whitworth on the Importance of Additional HER2 Subtyping

Pat Whitworth, MD, medical oncologist at the Nashville Breast Center, discusses the prospective neo-adjuvant NBRST study, which looked at BluePrint functional subtyping versus conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast tumors.